37 cases of Mycoplasma pneumoniae pneumonia were diagnosed in children in North Dakota, over 3.5 months (35 by PCR); 44% harbored macrolide-resistance. Children with macrolide-resistant M. pneumoniae had a longer period of coughing prior to diagnosis (+ 3.9 days, p=0.048), a longer duration of illness (+ 5.4 days, p=0.011) and earlier resolution of fever after initiation of doxycycline (- 0.92 days, p=0.025) compared to those without macrolide resistant M. pneumoniae.
Get full access to this article
View all access options for this article.
References
1.
WaitesKBRatliffACrabbDM, et alMacrolide-resistant Mycoplasma pneumoniae in the United States as determined from a national surveillance program. J Clin Microbiol. 2019;57(11):e00968-19.
2.
EdensCClopperBRDeViesJ, et alNotes from the field: reemergence of Mycoplasma pneumoniae infections in children and adolescents after the COVID-19 pandemic, United States, 2018-2024. MMWR Morb Mortal Wkly Rep. 2024;73(7):149-151.
3.
KimKJungSKimM, et alGlobal trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis. JAMA Netw Open. 2022;5(7):e2220949.
RothsteinTECunninghamSARiekeRAMainellaJMMutchlerMMPatelR.Macrolide resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021. Antimicrob Agents Chemother. 2022;66(4):e0243221.
6.
LeeHChoiYYSohnYJ, et alClinical efficacy of doxycycline for treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Antibiotics. 2021;10(2):192.
7.
SungMRohEJLeeES, et alAssessment of variables associated with prolonged admission duration in children with Mycoplasma pneumoniae pneumonia. Clin Respir J. 2022;16(11):756-767.
8.
OkadaTMorozumiMTajimaT, et alRapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children. Clin Infect Dis. 2012;55(12):1642-1649.
9.
LungDCYipEKLamDSQueTL.Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children. Pediatr Infect Dis J. 2013;32(12):1396-1399.
KawaiYMiyashitaNYamaguchiT, et alClinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients. Respirology. 2012;17(2):354-362.
12.
BolormaaEParkJYChoeYJKangCRChoeSAMylonakisE.Treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a meta-analysis of macrolides versus tetracyclines. Pediatr Infect Dis J. 2024;44:200-206. doi:10.1097/INF.0000000000004568.
13.
KuoCYTsaiWCLeeHF, et alThe epidemiology, clinical characteristics, and macrolide susceptibility of Mycoplasma pneumoniae pneumonia in children in Southern Taiwan, 2019–2020. J Microbiol Immunol Infect. 2022;55(4):611-619.
14.
American Academy of Pediatrics. Tetracyclines. In: KimberlinDWBradyMTJacksonMALongSS eds. Red Book: 2018 Report of the Committee on Infectious Diseases. 31st ed. Itasca, IL: American Academy of Pediatrics; 2018:905-906.
15.
Al-ZaidySAMacGregorDMahantSRichardsonSEBitnunA. Neurological complications of PCR-proven M. pneumoniae infections in children: prodromal illness duration may reflect pathogenetic mechanism. Clin Infect Dis. 2015;61:1092-1098.
16.
AvinerSMiskinHLondonDHorowitzSSchlesingerM.Mycoplasma pneumoniae infection: a possible trigger for immune thrombocytopenia. Indian J Hematol Blood Transfus. 2011;27:46-50.
17.
MartinoLDe RoseCMorelloR, et alMycoplasma pneumoniae mediastinal lymphadenitis in children: a case series and a review of the literature. Pediatr Infect Dis J. 2024;44:e68-e70.
